Osteoporosis

OFFICIAL LAUNCH OF THE NATIONAL UNIVERSITY SPINE INSTITUTE (NUSI): LEADING SPINE CARE INTO THE FUTURE

Retrieved on: 
Saturday, March 30, 2024
NUH, Research, Spinal stenosis, Conference, Health, MRI, National University Health System, Column (periodical), Radiology, Associate, Magnetic resonance imaging, Consultant, Education, Orthopedic surgery, Patient, Ageing, Degenerative disc disease, Knowledge, Artificial intelligence, Human, Deep learning, Deformity, National University Hospital, Scoliosis, Osteoporosis, Spine, Pain management, NUHS, Rehabilitation, Person, Nursing

SINGAPORE, March 30, 2024 /PRNewswire/ -- The National University Spine Institute (NUSI) is a new dedicated specialist spine institute under the National University Health System (NUHS) that provides multidisciplinary care for patients with spinal diseases and deformities.

Key Points: 
  • SINGAPORE, March 30, 2024 /PRNewswire/ -- The National University Spine Institute (NUSI) is a new dedicated specialist spine institute under the National University Health System (NUHS) that provides multidisciplinary care for patients with spinal diseases and deformities.
  • Under the leadership of Associate Professor Gabriel Liu, NUSI aims to set new standards in spine care through a patient-centric approach.
  • A/Prof Liu said: "NUSI differentiates itself by providing dedicated sub-specialties within the spine practice, standardising work processes and providing value-driven patient care across the cluster to address spinal problems.
  • NUSI is dedicated to developing community care programmes for patients, with cases expected to rise in the coming years partly due to an ageing population."

CVS Health® invests more than $3M in organizations improving health outcomes in Phoenix

Retrieved on: 
Wednesday, March 27, 2024
Blood pressure, Depression, Ozone, Overweight, Health, FQHC, Organization, Climate change, CVS, Project, Mental, Native Americans, Diabetes, Pharmacy, Conditional sentence, Patient, Education, CVS Pharmacy, Transport, Death, Quality of life, Senior, Bone density, City, CVS Health, Corporate social responsibility, Body mass index, Smoking, Osteoporosis, Suicide, American Lung Association, Cholesterol, Air pollution, Valleywise Health, Hypertension, Nursing

This announcement was made during a Project Health event in Phoenix and included CVS Health leaders, community organizations and local officials.

Key Points: 
  • This announcement was made during a Project Health event in Phoenix and included CVS Health leaders, community organizations and local officials.
  • "No two communities are the same," said Sheryl Burke, Senior Vice President of Corporate Social Responsibility and Chief Sustainability Officer at CVS Health.
  • With 65% of South Phoenix residents overweight or obese and knowing that 80% of health care costs are primarily due to preventable chronic diseases, CVS Health saw an opportunity to tailor its Health Zones initiative in Phoenix to address the high levels of diabetes and hypertension.
  • In addition to these new grants, CVS Health will offer free health screenings to the Phoenix community through its Project Health program, starting in March.

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

BUDAPEST, Hungary and NEW YORK, March 25, 2024 /PRNewswire/ -- TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, today announced that Gedeon Richter selected Trial Interactive's award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • "The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, "We're proud to be part of Gedeon Richter's plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services."

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

BUDAPEST, Hungary and NEW YORK, March 25, 2024 /PRNewswire/ -- TransPerfect Life Sciences, a leading global provider of solutions for product development and launch for the biopharmaceutical industry, today announced that Gedeon Richter selected Trial Interactive's award-winning eTMF platform and TI Collaborate eClinical solution for its upcoming clinical trials.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • "The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, "We're proud to be part of Gedeon Richter's plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services."

Bone Health and Osteoporosis Foundation Applauds President's Executive Order Directing Bold Action to Improve Care for Those With Osteoporosis

Retrieved on: 
Thursday, March 21, 2024
Milliman, Bone fracture, Bone health, First lady, Osteoporosis, White, Patient, Nursing, Fracture, Executive order, Research, HHS, Policy, Splenic infarction, Ageing, Laboratory, Stroke, Woman, Breast cancer, Medicare, Government, Federation, Dietary supplement

ARLINGTON, Va., March 21, 2024 /PRNewswire/ -- Earlier this week, President Biden issued a sweeping Executive Order directing Federal government agencies to take bold actions to improve women's health research and to assure that the "gains made in research laboratories are translated into real-world clinical benefits for women." In his published statement accompanying the Executive Order, the President specifically highlighted osteoporosis as a critical women's health condition that was being targeted for action. 

Key Points: 
  • In his published statement accompanying the Executive Order , the President specifically highlighted osteoporosis as a critical women's health condition that was being targeted for action.
  • Specifically, the White House statement says that the President is directing the Department of Health and Human Services (HHS) to "identify ways to improve … the clinical care that women receive" for diseases and conditions such as osteoporosis.
  • "This is a major victory for the 10 million Americans with osteoporosis," said Claire Gill, CEO of the Bone Health and Osteoporosis Foundation.
  • "We're grateful to President Biden and the First Lady for recognizing the need for action to help those with osteoporosis.

ClearChoice Dental Implant Centers Celebrates Opening of 100th Location in its Network

Retrieved on: 
Wednesday, March 13, 2024
Dentistry, Disease, Patient, 3D, Quality of life, Suite, American College, Osteoporosis, Mouth, Sun Capital Partners, DMD, Economic development

PARAMUS, N.J. and ROCHELLE PARK, N.J., March 13, 2024 /PRNewswire/ -- For the thousands of New Jersey residents experiencing dental pain and disease, there is something new to smile about as ClearChoice Dental Implant Center®, the national network that specializes in advanced oral disease and full mouth restorations, today announced the grand opening of the 100th center in its network in Rochelle Park, NJ. This marks a significant milestone in the network's  commitment to world-class dental implant options in the New Jersey/New York region and beyond, driven by the ClearChoice network's mission to deliver patient-centric, best-in-class solutions and techniques that can help improve the lives of those living with edentulism.

Key Points: 
  • The new center, located at 201 W Passaic Street, Suite 200 in Rochelle Park, will advance the ClearChoice Dental Implant Centers' delivery of all-inclusive dental implant services, thanks to an innovative model that consolidates the entire dental implant process under one roof.
  • The facility is owned and operated by Mark Andrawis, DMD, prosthodontist and owner of several ClearChoice Dental Implant Centers, including Roseland and Woodbridge, NJ, as well as Long Island City, Garden City, Albany, and Buffalo, NY.
  • This expansion reflects ClearChoice's ongoing commitment to accessible, high-quality dental implant services that streamline the patient experience, from consultation to completion.
  • The ClearChoice Network celebrated the occasion with a grand opening event at the new facility.

Therabody Expands Investment in Science with $10 Million Research Pledge, Scientific Partnerships and Official Scientific Advisory Board

Retrieved on: 
Tuesday, March 12, 2024
Exercise, Learning, Men's Health, Beauty, MSHS, Sports medicine, Hot, NFL, Physical, Research, Innovation, The New York Times, The Pew Charitable Trusts, Partnership, Private practice, Education, Harvard University, Mexico national football team, Policy, Bodybuilding.com, MLS, American College, Physical fitness, Medicine, Fatigue, Harvard Medical School, Metabolism, Longevity, Advisory board, Sport, Public, FACP, ACSM, Senior, Athlete, MPH, FACSM, LOS, DPT, Premiership Rugby, Physical activity, Doctor of Philosophy, Physical therapy, Quicksilver, CSCS, MLB, Johns Hopkins University, Red Bull, Osteoporosis, Bangladesh Technical Education Board, NBA, Physician

LOS ANGELES, March 12, 2024 /PRNewswire/ -- Therabody, the leader in wellness technology, announced today the investment of more than $10M to fund initiatives that will continue to drive innovation and the scientific validation of their products. The company also announced the formalization of their Scientific Advisory Board and, significantly, a partnership with the American College of Sports Medicine (ACSM), the global research leader in the field of exercise, physical fitness and sports medicine.

Key Points: 
  • In an evolving regulatory landscape, Therabody believes that science is essential for leading the way forward as technology will transform healthcare over the next decade.
  • Their $10 million investment in scientific research will drive an integrated strategy for scientific leadership in the industry with funds put toward scientific and clinical research studies across beauty, wellness and athletic performance over the next several years.
  • Our Scientific Advisory Board, along with our significant investment in scientific research and partnerships, will ensure we remain at the forefront of our industry and dedicated to developing the most effective, scientifically validated products available today and in the future," said Monty Sharma, President and CEO of Therabody.
  • Therabody has completed 21 scientific studies to date with 26 currently in progress.

Therabody Expands Investment in Science with $10 Million Research Pledge, Scientific Partnerships and Official Scientific Advisory Board

Retrieved on: 
Tuesday, March 12, 2024
Exercise, Learning, Men's Health, Beauty, MSHS, Sports medicine, Hot, NFL, Physical, Research, Innovation, The New York Times, The Pew Charitable Trusts, Partnership, Private practice, Education, Harvard University, Mexico national football team, Policy, Bodybuilding.com, MLS, American College, Physical fitness, Medicine, Fatigue, Harvard Medical School, Metabolism, Longevity, Advisory board, Sport, Public, FACP, ACSM, Senior, Athlete, MPH, FACSM, LOS, DPT, Premiership Rugby, Physical activity, Doctor of Philosophy, Physical therapy, Quicksilver, CSCS, MLB, Johns Hopkins University, Red Bull, Osteoporosis, Bangladesh Technical Education Board, NBA, Physician

LOS ANGELES, March 12, 2024 /PRNewswire/ -- Therabody, the leader in wellness technology, announced today the investment of more than $10M to fund initiatives that will continue to drive innovation and the scientific validation of their products. The company also announced the formalization of their Scientific Advisory Board and, significantly, a partnership with the American College of Sports Medicine (ACSM), the global research leader in the field of exercise, physical fitness and sports medicine.

Key Points: 
  • In an evolving regulatory landscape, Therabody believes that science is essential for leading the way forward as technology will transform healthcare over the next decade.
  • Their $10 million investment in scientific research will drive an integrated strategy for scientific leadership in the industry with funds put toward scientific and clinical research studies across beauty, wellness and athletic performance over the next several years.
  • Our Scientific Advisory Board, along with our significant investment in scientific research and partnerships, will ensure we remain at the forefront of our industry and dedicated to developing the most effective, scientifically validated products available today and in the future," said Monty Sharma, President and CEO of Therabody.
  • Therabody has completed 21 scientific studies to date with 26 currently in progress.

Flavonoid Market to Reach $2,926.7 million, Globally, by 2032 at 5.8% CAGR: Allied Market Research  

Retrieved on: 
Monday, March 11, 2024
Cardiovascular disease, Anthocyanin, Prevalence, Dietary supplement, Conditional sentence, Functional food, Flavonoid, Infant, Cancer, Food, Isoflavone, Woman, Acne, Atherosclerosis, Osteoporosis, Hot, Pharmaceutical industry

PORTLAND, Ore., March 11, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Flavonoid Market By Product Type (Isoflavones, Anthocyanin, Others), By Form (Powder, Liquid), By Application (Pharmaceuticals, Nutraceuticals, Cosmetics, Food And Beverages).". According to the report, the global Flavonoid Market generated $1,672.2 million in 2022 and is anticipated to generate $2,926.7 million by 2032, witnessing a CAGR of 5.8% from 2023 to 2032.  

Key Points: 
  • However, the anthocyanin segment is projected to manifest the highest CAGR of 6.3% from 2023 to 2032.
  • Rise in food & beverage coloring agents market including synthetic and natural colors is expected to increase the demand for Anthocyanin from various industries during the forecast period.
  • Based on form, the powder segment held the highest market share in 2022, accounting for more the four-fifth of the global flavonoid market revenue and is estimated to maintain its leadership status throughout the forecast period.
  • However, the Food and Beverages segment is projected to manifest the highest CAGR of 6.3% from 2023 to 2032.

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 8, 2024
OXM, Woman, Injection, Research, Bone fracture, Clinical research associate, Type D, FDA, BMD, PTH, Food, Hypoparathyroidism, Obesity, Coeliac disease, Weight loss, Oxyntomodulin, Cmax, Elective surgery, Sport, Short bowel syndrome, OPKO Health, DSM-IV codes, Ecosystem, SABRE, Patient, D&O, Intellectual property, Fracture, Athlete, Sports medicine, Tablet, Osteoporosis, Insurance

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
  • Following our December 2023 financing, we expect to have sufficient cash to fund operations through the first half of 2025,” said Miranda Toledano, CEO of Entera.
  • Financial Results for the year Ended December 31, 2023
    As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million.
  • Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.